Remarks

The specification has been amended as shown to clarify FIG. 1 as originally filed on April 19, 2004. In fact, there is only one FIG. 1. There are no additional views A, B, or C. Instead, three different data points are shown within FIG. 1. The reference to FIG. 1A - 1C in the original application was a typographical error that has now been corrected by this Preliminary Amendment. No change to FIG. 1 is needed, and none has been made. Therefore, no new matter is presented herein.

It is respectfully submitted that all pending claims are in condition for allowance, and respectfully request that allowance be granted at the earliest date possible. Should the Examiner have any questions or comments regarding Applicant's amendment, the Examiner is asked to contact Applicant's undersigned representative at (215) 575-7034.

If there are any fees due in connection with the filing of this response, please charge the fees to our Deposit Account No. 50-0979.

Respectfully submitted,

Evelyn H. McConathy Registration No. 35,279

Date: August 24, 2004

DILWORTH PAXSON LLP 3200 Mellon Bank Center 1735 Market Street Philadelphia, PA 19103-7595 Tel. (215) 575-7000 Fax (215) 575-7200

In the Description of the Drawings:

Please replace the paragraph beginning at page 12, line 18, with the following rewritten paragraph:

FIG. 1 [FIGs. 1A-1C] graphically display (s) the frequency (%) of CD4+CD25+ lymphocytes present in total CD4+ cells isolated from lung cancer tumor specimens as compared with the peripheral blood lymphocytes (PBL) of lung cancer patients as determined by flow cytometry. Distributions and means are shown: PBL of normal donors, n=7 [left]; unstimulated tumor infiltrating lymphocytes (TIL) from patients with NSCLC, n=8 [center]; or unstimulated PBL from patients with NSCLC, n=9 [right]. P values were calculated using the Student 2-tailed t test.

In the Examples:

Please replace the paragraph beginning at page 38, line 11, with the following rewritten paragraph:

Thus, when the frequency (%) of CD4+CD25+ lymphocytes present in the total CD4+ cells population isolated from lung cancer tumor specimens as compared with the peripheral blood lymphocytes (PBL) of the lung cancer patients was determined by flow cytometry, it was determined that 33% of the tumor infiltrating lymphocytes (TIL) were CD4+CD25+. This was consistent with the activated phenotype of regulatory T cells. In FIG. 1, the distributions and means are shown as PBL of normal donors, n=7 [FIG. 1A]; unstimulated tumor infiltrating lymphocytes (TIL) from patients with NSCLC, n=8 [FIG. 1B]; or unstimulated PBL from patients with NSCLC, n=9 [FIG. 1C]. Notably, the peripheral blood of patients with NSCLC had a similar increase in the percentages of CD4+CD25+ cells.